<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04383418</url>
  </required_header>
  <id_info>
    <org_study_id>HR0171401-301</org_study_id>
    <nct_id>NCT04383418</nct_id>
  </id_info>
  <brief_title>A Trial of Dexmedetomidine Hydrochloride Nasal Spray in Preoperative Sedation of Adults</brief_title>
  <official_title>Study on Efficacy and Safety of Dexmedetomidine Hydrochloride Nasal Spray for Preoperative Sedation in Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu HengRui Medicine Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu HengRui Medicine Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is being conducted to evaluate the efficacy, and safety of dexmedetomidine
      hydrochloride nasal spray for preoperative sedation in adults. To explore the reasonable
      dosage of dexmedetomidine hydrochloride nasal spray for preoperative sedation.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 21, 2020</start_date>
  <completion_date type="Anticipated">October 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2020</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Dexmedetomidine hydrochloride nasal spray compared with placebo</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of subjects who meet the Ramsay sedation score of 3 at least once within 45 minutes</measure>
    <time_frame>0 minute to 45 minutes after administration</time_frame>
    <description>Evaluated with Ramsay sedation scale Score Response
Anxious or restless or both
Cooperative, orientated and tranquil
Responding to commands
Brisk response to stimulus
Sluggish response to stimulus
No response to stimulus</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total consumption of propofol during bispectral index reaches 60 for the first time</measure>
    <time_frame>The bispectral index reaches 60 for the first time during intraoperative</time_frame>
    <description>Total consumption of propofol during bispectral index reaches 60 for the first time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total consumption of propofol during general anesthesia</measure>
    <time_frame>From the beginning of anesthesia to the end of surgical operation up to 4 hours</time_frame>
    <description>Total consumption of propofol during general anesthesia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total consumption of opioid analgesic during bispectral index reaches 60 for the first time</measure>
    <time_frame>The bispectral index reaches 60 for the first time during intraoperative</time_frame>
    <description>Total consumption of opioid analgesic during bispectral index reaches 60 for the first time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total consumption of opioid analgesic during general anesthesia</measure>
    <time_frame>From the beginning of anesthesia to the end of surgical operation up to 4 hours</time_frame>
    <description>Total consumption of opioid analgesic during general anesthesia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The BIS value for the Ramsay sedation score of 3 for the first time after administration</measure>
    <time_frame>The Ramsay sedation score of 3 for the first time during intraoperative</time_frame>
    <description>The BIS value for the Ramsay sedation score of 3 for the first time after administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anesthesiologist satisfaction rating</measure>
    <time_frame>At the end of surgery when the patient recovers from anesthesia</time_frame>
    <description>The anesthesiologist satisfaction rating is a scale of 0 to 10, satisfaction defined as a scale of 10, dissatisfaction defined as a scale of 0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjects' satisfaction rating</measure>
    <time_frame>From the end of surgical operation up to 24 hours</time_frame>
    <description>The subjects' satisfaction rating is a scale of 0 to 10, satisfaction defined as a scale of 10, dissatisfaction defined as a scale of 0.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">108</enrollment>
  <condition>Preoperative Sedation</condition>
  <arm_group>
    <arm_group_label>High dose group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In the low dose group, 36 subjects will receive a low dose of dexmedetomidine nasal spray.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low dose group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In the high dose group, 36 subjects will receive a high dose of dexmedetomidine nasal spray.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>In the placebo groupï¼Œ36 subjects will receive dexmedetomidine hydrochloride nasal spray blank preparation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dexmedetomidine nasal spray</intervention_name>
    <description>dexmedetomidine nasal spray</description>
    <arm_group_label>High dose group</arm_group_label>
    <arm_group_label>Low dose group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dexmedetomidine hydrochloride nasal spray blank preparation</intervention_name>
    <description>dexmedetomidine hydrochloride nasal spray blank preparation</description>
    <arm_group_label>Placebo group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Able and willing to provide a written informed consent

          2. Subjects requiring elective general anesthesia surgery

          3. Male or female

          4. Meet the weight standard

          5. Conform to the ASA Physical Status Classification

        Exclusion Criteria:

          1. Not suitable for nasal spray

          2. Subjects who had received general anesthesia

          3. Subjects with a history of myocardial infarction or unstable angina pectoris

          4. Subjects with atrioventricular block or cardiac insufficiency

          5. Subjects with a history of ischemic stroke or transient ischemic attack

          6. Subjects with poor blood pressure control after medication

          7. Subjects with abnormal clotting function

          8. Subjects with a history of mental illness and a history of cognitive impairment
             epilepsy

          9. Subjects with a history or possibility of a difficult airway

         10. Subject with a history of substance abuse and drug abuse

         11. Adrenoceptor agonists or antagonists were used before randomization

         12. Abnormal values in the laboratory

         13. Thyroid dysfunction

         14. Allergic to a drug ingredient or component

         15. Pregnant or nursing women

         16. No birth control during the specified period of time

         17. Participated in clinical trials of other drugs (received experimental drugs)

         18. The inestigators determined that other conditions were inappropriate for participation
             in this clinical trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Changhong Miao, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Zhongshan Hospital, Fudan University, Shanghai</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Changhong Miao, PhD</last_name>
    <phone>13681975062</phone>
    <email>miaochh@aliyun.com</email>
  </overall_contact>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>May 6, 2020</study_first_submitted>
  <study_first_submitted_qc>May 7, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 12, 2020</study_first_posted>
  <last_update_submitted>May 7, 2020</last_update_submitted>
  <last_update_submitted_qc>May 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexmedetomidine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

